Pharmacogenomic Guidance Could Foretell Upcoming Diagnostics Draft
This article was originally published in The Gray Sheet
Executive Summary
FDA will not use genomic information voluntarily submitted by industry for regulatory decisions on drug or biologics applications, according to a guidance issued March 22